Luis Antonio Ruiz-Avila

Luis Antonio Ruiz-Avila

Chief Executive Officer at Leukos Biotech SL

Health Technology
Consumer Services
Commercial Services

Profile

Luis Antonio Ruiz-Avila is currently the Chief Executive Officer at Leukos Biotech SL since 2019 and at Immuni Therapeutics SL since 2020.
He is also the Chairman at Aquilón Cyl SL and a Director at Kintsugi Therapeutics.
Previously, he served as the Chief Executive Officer at Archivel Farma SL.
He was also the Director at Asociacion De Empresas Biotecnologicas in 2008.
Additionally, he worked as a Principal at Icahn School of Medicine at Mount Sinai.
Prior to that, he was a Project Manager at Almirall Ltd.
from 1997 to 2001.
Dr. Ruiz-Avila obtained his undergraduate and doctorate degrees from the University of Barcelona.

Luis Antonio Ruiz-Avila active positions

CompaniesPositionStart
Chairman -
Chief Executive Officer 2020-08-31
Chief Executive Officer 2019-09-30
Director/Board Member -
All active positions of Luis Antonio Ruiz-Avila

Former positions of Luis Antonio Ruiz-Avila

CompaniesPositionEnd
Director/Board Member 2007-12-31
Corporate Officer/Principal 2000-12-31
Chief Executive Officer -
Icahn School of Medicine at Mount Sinai Corporate Officer/Principal -
See the detail of Luis Antonio Ruiz-Avila's experience

Training of Luis Antonio Ruiz-Avila

University of Barcelona Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Luis Antonio Ruiz-Avila's experience

Connections

7

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies7

Commercial Services

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Luis Antonio Ruiz-Avila